Fosifloxuridine Nafalbenamide is a small molecule commercialized by NuCana, with a leading Phase III program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Fosifloxuridine Nafalbenamide’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Fosifloxuridine Nafalbenamide is expected to reach an annual total of $195 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Fosifloxuridine Nafalbenamide Overview

Fosifloxuridine nafalbenamide (NUC-3373) is under development for the treatment of advanced solid tumors including colorectal cancer, cholangiocarcinoma, pleural mesothelioma, basal cell carcinoma, non-small cell lung cancer. The drug candidate consists of the active anti-cancer metabolite, FUDR-MP and a protective phosphoramidate moiety. It is a small molecule administered intravenously. The drug candidate is developed based on Protide technology platform.
It was also under development for the treatment of advanced breast cancer.

NuCana Overview

NuCana, formerly NuCana BioMed, is a clinical-stage biopharmaceutical company. It focuses on developing novel and transformational medicines for cancer treatments. Its key products include Acelarin, which is in phase III clinical studies, and used to treat biliary tract cancer. The company is also developing products such as NUC-3373 and NUC-7738, which are under Phase I study and used to treat solid tumors. NuCana develops products based on the ProTide technology platform, which focuses on developing new generation, anti-cancer agents. The company markets its products in the UK and the US. NuCana is headquartered in Edinburgh, the UK.

The operating loss of the company was GBP39.1 million in FY2022, compared to an operating loss of GBP47.9 million in FY2021. The net loss of the company was GBP32 million in FY2022, compared to a net loss of GBP40.5 million in FY2021.

For a complete picture of Fosifloxuridine Nafalbenamide’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.